**DATES:** Comments on the ICR must be received on or before November 15, 2022.

**ADDRESSES:** Submit your comments to *Sherrette.Funn@hhs.gov* or by calling (202) 795–7714.

#### FOR FURTHER INFORMATION CONTACT:

When submitting comments or requesting information, please include the document identifier 0990—New—60D and project title for reference, to Sherrette A. Funn, email: Sherrette.Funn@hhs.gov, or call (202) 795—7714 the Reports Clearance Officer.

**SUPPLEMENTARY INFORMATION:** Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of

information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Title of the Collection: Data Management Standard Operating Procedures Survey.

Type of Collection: New. OMB No.: 0990-New.

Abstract: The Office of the Assistant Secretary for Health, Office of Research

Integrity is requesting a new approval from the Office of Management and Budget of the Data Management Standard Operating Procedures Survey. Information from respondents to the survey will be used to develop a Data Management Standard Operating Procedures toolkit that will be disseminated to researchers, research administrators, and research institutions to implement. In addition, other products will be developed to disseminate survey results and findings to include, social media posts, YouTube video, webinar, and summary report for the research community.

*Likely Respondents:* Biostatisticians and Bioscience Researchers.

### ANNUALIZED BURDEN HOUR TABLE

| Form name   | Type of respondent                           | Number of respondents | Number of responses per respondent | Average<br>burden<br>per response<br>(in hours) | Total<br>burden hours |
|---|--|-----------------------|------------------------------------|---|-----------------------|
| Data Management Standard Operating Procedures Survey. | Biostatisticians and Bioscience Researchers. | 1,200                 | 1                                  | 45/60   | 900                   |
| Total   |  |                       |                                    |   | 900                   |

### Sherrette A. Funn,

Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.

[FR Doc. 2022-20115 Filed 9-15-22; 8:45 am]

BILLING CODE 4150-31-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

# Findings of Research Misconduct; Correction

**AGENCY:** Office of the Secretary, HHS. **ACTION:** Correction of notice.

**SUMMARY:** This document corrects errors that appeared in the notice published in the August 5, 2022, **Federal Register** entitled "Findings of Research Misconduct."

Applicability Date: The correction notice is applicable for the Findings of Research Misconduct notice published on August 5, 2022.

FOR FURTHER INFORMATION CONTACT: Dr. Alexander Runko or Ms. Karen Gorirossi at 240-453-8800.

## SUPPLEMENTARY INFORMATION:

### I. Background

In FR Doc. 2022–16867 of August 5, 2022 (87 FR 48034–48036), there were errors involving National Institutes of Health (NIH) grant application UL1 TR000124 affecting six paragraphs on

page 48035. The errors are identified and corrected in the Correction of Errors section below.

## **II. Correction of Errors**

Due to additional information provided by the institution to the Office of Research Integrity, it was determined that NIH grant application UL1 TR000124 did not fund or contain falsified/fabricated data; therefore, this grant application has been removed from the findings of research misconduct reported in FR Doc. 2022–16867. Thus, in FR Doc. 2022–16867 of August 5, 2022 (87 FR 48034–48036), make the following corrections:

- 1. On page 48035, first column, in FR Doc. 2022–16867, first paragraph, lines 9–12, remove "UL1 TR000124 submitted to the National Center for Advancing Translational Sciences (NCATS), NIH."
- 2. On page 48035, first column, in FR Doc. 2022–16867, fourth paragraph, lines 14–15, remove "UL TR000124 submitted to NCATS, NIH."
- 3. On page 48035, first column, in FR Doc. 2022–16867, fifth paragraph, lines 5–6, change "eleven (11) grant applications" to "ten (10) grant applications."
- 4. On page 48035, first column, in FR Doc. 2022–16867, seventh paragraph, lines 1–2, and second column, in FR Doc. 2022–16867, first paragraph, lines 1–3, remove "UL1 TR000124, 'UCLA

Clinical and Translational Science Institute,' submitted to NCATS, NIH, Awarded Project Dates: June 1, 2011– August 31, 2016."

5. On page 48035, second column, in FR Doc. 2022–16867, thirteenth paragraph, line 1, remove "Figure 6 of UL1 TR000124."

Dated: September 13, 2022.

# Wanda K. Jones,

Acting Director, Office of Research Integrity, Office of the Assistant Secretary for Health. [FR Doc. 2022–20070 Filed 9–15–22; 8:45 am]

BILLING CODE 4150-31-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# **Meeting of the Tick-Borne Disease Working Group**

**AGENCY:** Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

SUMMARY: As required by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the Tick-Borne Disease Working Group (TBDWG) will hold a meeting. The meeting will be open to the public via webcast. For this meeting, the TBDWG will review and vote upon the

third and final Report to Congress and the HHS Secretary. The 2022 report will address a wide range of topics related to tick-borne diseases, such as, surveillance, prevention, diagnosis, diagnostics, and treatment; identify advances made in research, as well as overlap and gaps in tick-borne disease research; and provide recommendations regarding any appropriate changes or improvements to such activities and research.

DATES: The public can view the meeting online via webcast on October 25, 2022 from approximately 9:00 a.m. to 5:00 p.m. ET (times are tentative and subject to change) each day. The confirmed times and agenda items for the meeting will be posted on the TBDWG web page at <a href="https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/2022-10-25/index.html">https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/2022-10-25/index.html</a> when this information becomes available.

### FOR FURTHER INFORMATION CONTACT:

James Berger, Designated Federal Officer for the TBDWG; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Tower Building, 1101 Wootton Parkway, Rockville, MD 20852. Email: tickbornedisease@hhs.gov. Phone: 202–795–7608.

SUPPLEMENTARY INFORMATION: A link to

view the webcast can be found on the meeting website at https://www.hhs.gov/ ash/advisory-committees/ tickbornedisease/meetings/2022-10-25/ index.html when it becomes available. The public will have an opportunity to present their views to the TBDWG orally during the meeting's public comment session or by submitting a written public comment. Comments should be pertinent to the meeting discussion. Persons who wish to provide verbal or written public comment should review instructions at https://www.hhs.gov/ ash/advisorv-committees/ tickbornedisease/meetings/2022-10-25/ index.html and respond by midnight October 17, 2022 ET. Verbal comments will be limited to three minutes each to

web page prior to the meeting.

Background and Authority: The Tick-Borne Disease Working Group was established on August 10, 2017, in accordance with section 2062 of the 21st Century Cures Act, and the Federal Advisory Committee Act, 5 U.S.C. app., as amended, to provide expertise and review federal efforts related to all tick-borne diseases, to help ensure interagency coordination and minimize

accommodate as many speakers as

Written public comments will be

possible during the 30-minute session.

accessible to the public on the TBDWG

overlap, and to examine research priorities. The TBDWG is required to submit a report to the HHS Secretary and Congress on their findings and any recommendations for the federal response to tick-borne disease every two years.

Dated: September 8, 2022.

#### James J. Berger,

Designated Federal Officer, Tick-Borne Disease Working Group, Office of Infectious Disease and HIV/AIDS Policy.

[FR Doc. 2022–20088 Filed 9–15–22; 8:45 am]

BILLING CODE 4150-28-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

## Office of the Secretary; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Science Advisory Board for Biosecurity.

The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (http://videocast.nih.gov/).

Name of Committee: National Science Advisory Board for Biosecurity.

Date: September 21, 2022. Time: 1:00 p.m. to 5:00 p.m.

Agenda: The National Science Advisory Board for Biosecurity (NSABB) meeting will include a progress update from the NSABB Working Group to Review and Evaluate Potential Pandemic Pathogen Care and Oversight (PC3O) Policy, and stakeholder engagement on topics related to the U.S. Government policies for the Oversight of Dual Use Research of Concern (DURC).

Place: National Institutes of Health, 6705 Rockledge Drive, Suite 630, Bethesda, MD 20892, (Virtual Meeting Link will be available at https://osp.od.nih.gov/biotechnology/national-science-advisory-board-for-biosecurity-nsabb/#meetings).

Contact Person: Cari Young, ScM, Acting Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy, Office of Science Policy, Office of the Director, National Institutes of Health, 6705 Rockledge Drive, Suite 630, Bethesda, MD 20892, (301) 594–3746, SciencePolicy@od.nih.gov.

To sign up to make an oral public comment at the meeting, please send an email to the Contact Person listed above at least one business day prior to the meeting date. Once all time slots are filled, only written comments will be accepted. Any interested

person may file written comments by forwarding the statement to the Contact Person listed on this notice at least one business day prior to the meeting date. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person. Other than name and contact information, please do not include any personally identifiable information or any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your comments. Please note that any written comments NIH receives may be posted unredacted to the Office of Science Policy website.

Information is also available on the NIH Office of Science Policy website: https://osp.od.nih.gov/biotechnology/national-science-advisory-board-for-biosecurity-nsabb/#meetings, where an agenda, link to the webcast meeting, and any additional information for the meeting will be posted when available. Materials for this meeting will be posted prior to the meeting. Please check this website for updates.

This notice is being published less than 15 days prior to the meeting due to scheduling difficulties.

Dated: September 13, 2022.

### Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-20098 Filed 9-15-22; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **National Institutes of Health**

## Submission for OMB Review; 30-Day Comment Request; The Clinical Trials Reporting Program (CTRP) Database (NCI)

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under 30-day Review—Open